As an oral hepatoselective GKA initially discovered for potential unmet medical needs of patients with T2D, TTP399 does not activate GK in pancreatic β‐cells, and there were no changes in fasting active GLP‐1, lactate, insulin, or C‐peptide levels during the trial. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.